

lymphoblastic leukemia, null cell
acute lymphoblastic leukemia, or B
cell chronic lymphatic leukemia;

- B1*
- d) reacts weakly with the human T cell line HJD-1 but does not react with CEM, Laz 191, or HM1;
 - e) does not react with the Epstein-Barr virus-transformed human B cell lines Laz 007, Laz 156, Laz 256, or SB; and
 - f) fixes complement.

17. (amended) A method for preparing monoclonal antibody which:

- B2*
- a) reacts with essentially all normal human peripheral T cells and cutaneous T lymphoma cells, but not with normal human peripheral B cells, null cells or macrophages;
 - b) reacts with from about 5% to about 10% of normal human thymocytes;
 - c) reacts with leukemic cells from humans with T cell chronic lymphoblastic leukemia but does not react with leukemic cells from humans with T cell acute lymphoblastic leukemia, null cell acute lymphoblastic leukemia, or B cell chronic lymphatic leukemia;
 - d) reacts weakly with the human T cell line HJD-1 but does not react with CEM, Laz 191, or HM1;
 - e) does not react with the Epstein-Barr virus-transformed human B cell lines Laz 007, Laz 156, Laz 256, or SB; and

f) fixes complement,
which comprises the steps of:

- i) immunizing mice with E rosette positive purified human T cells;
- ii) removing the spleens from said mice and making a suspension of the spleen cells;
- iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter;
- iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells;
- v) evaluating the supernatant in each well containing a hybridoma for the presence of the desired antibody;
- vi) selecting and cloning hybridomas producing the desired antibody;
- [vii) recovering the antibody from the supernatant above said clones;]
- viii) transferring said clones intra-peritoneally into mice; and
- ix) harvesting the malignant ascites or serum from said mice[.], which ascites or serum contains the desired antibody.

Kindly cancel Claims 4-14 and 19-21.

Add the following new claims:

22. Mouse complement-fixing monoclonal antibody which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages.

823. A method of preparing complement-fixing monoclonal antibody which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages, which comprises culturing the hybridoma ATCC CRL 8001 in a suitable medium and recovering the antibody from the supernatant above said hybridoma.

1024. A method of preparing complement-fixing monoclonal antibody which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages, which comprises injecting into a mouse the hybridoma ATCC CRL 8001 and recovering the antibody from the malignant ascites or serum of said mouse.

625. A ~~method for preparing~~ complement-fixing monoclonal antibody which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages, which comprises the steps of:

- i) immunizing mice with E rosette positive purified human T cells;
- ii) removing the spleens from said mice and making a suspension of the spleen cells;
- iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter;
- iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells;
- v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells;

- vi) selecting and cloning a hybridoma producing antibody which fixes complement and reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages; and
- vii) recovering the antibody from the supernatant above said clones.

DC 7. A ~~method for preparing~~ ^{complement-fixing} monoclonal antibody which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages, ^{prepared by the method} which comprises the steps of:

Q
B

- i) immunizing mice with E rosette positive purified human T cells;
- ii) removing the spleens from said mice and making a suspension of the spleen cells;
- iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter;
- iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells;
- v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells;
- vi) selecting and cloning a hybridoma producing antibody which fixes complement and reacts with essentially all normal human peripheral